Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in global Phase 3 trials for obesity with key data expected in 2028, while other candidates progress through earlier trial phases. Kailera has a multi-billion-dollar licensing partnership with Jiangsu Hengrui Pharmaceuticals, with rights outside Greater China available for acquisition. Potential buyers include major pharma firms like Pfizer, AstraZeneca, Merck, Novo Nordisk, AbbVie, and Amgen. Analysts remain optimistic, rating Kailera a Buy with a target price of $42.40, eyeing upcoming trial data as key catalysts.
Pfizer is considered a cautious Buy, trading near its intrinsic value with an expected 10% annual return mainly from its high dividend yield. However, the company faces significant challenges including a looming patent cliff, a stretched balance shee...
Galmed Pharmaceuticals announced preclinical results showing that combining Aramchol with Xtandi (enzalutamide) increased prostate cancer cell death by 3-4 times compared to Xtandi alone. Xtandi, a major prostate cancer drug with global sales of $8 b...
